Company intelligence / Profile preview

SignalRx Pharmaceuticals

Ownership: Private
Employees: ~8
Development stage: Phase 1

Overview

Focus on multi-target small molecules, emphasis on synergistic pathway inhibition, active collaborations for drug delivery systems. Notable candidate SFX2523 inhaled formulation in development for lung pathologies. Preclinical data shows broad anticancer activity across multiple cancer types. Ongoing research on BRD4-based therapeutics and DNA methyltransferase inhibitors.

Therapeutic areas: OncologyPulmonologyInfectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

8 assets

SF1126

7 more assets in the full pipeline.

Request access →

Partnerships

Crystec PharmaADYA Consulting

Beyond the preview

Go deeper on SignalRx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignalRx Pharmaceuticals.

Explore the full profile